Sprague-Dawley rats were administered low doses of metronidazole similar to those used in humans, and then subjected to a long-term follow-up. Metronidazole caused a significant rise in mammary tumors in the female rats (p < 0.001) after a mean latency period of 100.5 weeks.
Get full access to this article
View all access options for this article.
References
1.
BeardC.M., NollerK.L., O'FallonW.M., KurlandL.T., DockertyM.B.: Lack of evidence for cancer due to use of metronidazole.N. Engl. J. Med., 301: 519–522, 1979.
2.
CavaliereA., BacciM., AmorosiA., Del GaudioM., VitaliR.: Induction of lung tumors and lymphomas in BALB/c mice by metronidazole.Tumori, 69: 379–382, 1983.
3.
CohenS.M., ErtürkF., Von EschA.M., CrovettiA.J., BryanG.: Carcinogenicity of 5-nitrofurans, 5-nitroimidazoles, 4-nitrobenzenes, and related compounds.J. Natl. Cancer Inst., 51: 403–417, 1973.
4.
ConnorT.H., StoeckelM., EvrardJ., LegatorM.S.: The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice.Cancer Res., 37: 629–633, 1977.
5.
DeutschG., FosterJ.L., McFadzeanJ.A., ParnellM.: Human studies with « high dose » metronidazole.A non-toxic radiosensitizer of hypoxic cells. Br. J. Cancer, 31: 75–80, 1975.
6.
FriedmanG.D.: Cancer after metronidazole.N. Engl. J. Med., 302: 519, 1980.
GoodmanL.S., GilmanA.: The Pharmacological Basis of Therapeutics. pp. 1072–1073, 1086–1088, McMillan, New York, 1975.
9.
LegatorM.S., ConnorT.H., StoeckelM.: Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice.Science, 188: 1118–1119, 1975.
10.
LindmarkD.G., MüllerM.: Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles.Antimicrob. Agents Chemother., 10: 476–482, 1976.
11.
PetoR., PikeM.C., ArmitageP., BreslowN.E., CoxD.R., HowardS.V., MantelN., McPhersonK., PetoJ., SmithP.G.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient.II. Analysis and examples. Br. J. Cancer, 35: 1–39, 1977.
12.
PetoR., PikeM.C., DayN.E., GrayR.G., LeeP.N., ParishS., PetoJ., RichardsS., WahrendorfJ.: Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Suppl. 2, Long-term and short-term screening assays for carcinogens: A critical appraisal., pp. 311–426, Lyon, France, 1980.
13.
RoeF.J.C.: A critical appraisal of the toxicology of metronidazole. In: Metronidazole.PhillipsI., and CollierJ., Eds., pp. 215–222, Academic Press, London, 1979.
14.
RoeF.J.C.: Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential.Surgery, 93: 158–164, 1983.
15.
RosenkranzH.S., SpeckW.T.: Mutagenicity of metronidazole: activation by mammalian liver microsomes.Biochem. Biophys. Res. Commun., 66: 520–525, 1975.
16.
RustJ.H.: An assessment of metronidazole tumorigenicity: Studies in the mouse and rat. In: Metronidazole. Proceedings of the International Metronidazole Conference, Montreal, Quebec, Canada.FinegoldS.M., McFadzeanJ.A., and RoeF.J.C., Eds., pp. 138–144, Excerpta Medica, Amsterdam, 1977.
17.
RustiaM., ShubikP.: Induction of lung tumors and malignant lymphomas in mice by metronidazole.J. Natl. Cancer Inst., 48: 721–729, 1972.
18.
RustiaM., ShubikP.: Experimental induction of hepatomas, mammary tumors, and other tumors with metronidazole in noninbred Sas:MRC(WI)BR rats.J. Natl. Cancer Inst., 63: 863–868, 1979.
19.
SchipperH., BealeF.A., BushR.S., FryerC.: Metronidazole as a radiosensitizer.N. Engl. J. Med., 295: 901, 1976.
20.
SpeckW., SteinA.B., RosenkranzH.S.: Mutagenicity of metronidazole: Presence of several active metabolites in human urine.J. Natl. Cancer Inst., 56: 283–284, 1976.
21.
UrsingB., KammeC.: Metronidazole for Crohn's disease.Lancet, 1: 775–777, 1975.
